This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Click here for Great Britain and Northern Ireland Prescribing Information for MYLOTARG®▼ (gemtuzumab ozogamicin) and cytarabine.
Adverse event reporting information can be found at the bottom of the page.

PubExplainer videos

Three animated videos which explain in a clear and succinct way:​​​​​​​
​​​​​​​
  1. Mechanism of action and the fractionated dosing schedule for MYLOTARG
  2. The key data from the Phase III ALFA-0701 study
  3. Measurable residual disease (MRD) and why it matters

Mechanism of action and the Fractionated dosing schedule for MYLOTARG

A short video (3.03 duration) explaining
-MYLOTARG's mechanism of action
-Leading to the rationale of MYLOTARG's fractionated dosing schedule
-The resulting efficacy and safety data from the ALFA-0701 study
-Summary of the NICE recommendation

ALFA-0701 study

A quick video (03.26 duration) that covers all the key points related to the pivotal Phase III ALFA-0701 study
- Study Design
- Baseline characteristics
- Induction and Consolidation courses
- Primary endpoint: Event Free survival results by cytogenetic group
- Secondary endpoint: Relapse Free Survival results
- Adverse Events reported​​​​​​​

What is MRD and why does it matter?

This video (3.33 duration) aims to illustrate the concept of MRD by aggregating findings from different disease areas, studies and results. Its main focus is on Acute Lymphoblastic Leukaemia and data on  Acute Myeloid Leukaemia is shown at time point 2.40. 
This video covers:
-Definition of MRD
-Detection
-Principles
-Relevance: Complete remission
-Impact on Survival rates and patient outcomes

Explore more

Download the fast facts PDF document to aid your understanding of MYLOTARG

Download the pdf

AML, Acute Myeloid Leukaemia; MRD, measurable residual disease


PP-MYL-GBR-0540. March 2022

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Quick Links

Understand the evidence

Guidelines

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?